WeRide Inc. (WRD)
NASDAQ: WRD · Real-Time Price · USD
8.65
-0.53 (-5.77%)
At close: Aug 1, 2025, 4:00 PM
8.68
+0.03 (0.34%)
After-hours: Aug 1, 2025, 7:59 PM EDT
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts that cover Revance Therapeutics stock have a consensus rating of "Buy" and an average price target of $22, which forecasts a 154.34% increase in the stock price over the next year. The lowest target is $21 and the highest is $23.
Price Target: $22.00 (+154.34%)
Analyst Consensus: Buy
* Price targets were last updated on Jan 24, 2025.
Analyst Ratings
The average analyst rating for Revance Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Initiates $21 | Buy | Initiates | $21 | +142.77% | Jan 24, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $23 | Buy | Initiates | $23 | +165.90% | Nov 19, 2024 |
| Raymond James | Raymond James | Strong Buy → Buy Downgrades $30 | Strong Buy → Buy | Downgrades | $30 | +246.82% | Nov 6, 2018 |
| B of A Securities | B of A Securities | Strong Buy Maintains $22 → $23 | Strong Buy | Maintains | $22 → $23 | +165.90% | Feb 13, 2018 |
| Barclays | Barclays | Buy Maintains $19 → $21 | Buy | Maintains | $19 → $21 | +142.77% | Nov 20, 2017 |
Financial Forecast
Revenue This Year
106.27M
from 361.13M
Decreased by -70.57%
Revenue Next Year
338.93M
from 106.27M
Increased by 218.93%
EPS This Year
-0.38
from -25.63
EPS Next Year
-0.26
from -0.38
Financial currency is CNY. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 154.5M | 483.1M | 1.6B |
| Avg | 106.3M | 338.9M | 1.5B |
| Low | 80.8M | 192.2M | 1.4B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -57.2% | 354.6% | 374.4% |
| Avg | -70.6% | 218.9% | 339.0% |
| Low | -77.6% | 80.9% | 309.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.16 | -0.03 | 0.06 |
| Avg | -0.38 | -0.26 | 0.05 |
| Low | -0.67 | -0.49 | 0.04 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.